Evergreen Capital Management LLC Acquires 212 Shares of Stryker Co. (NYSE:SYK)

Evergreen Capital Management LLC lifted its stake in Stryker Co. (NYSE:SYK) by 5.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,259 shares of the medical technology company’s stock after acquiring an additional 212 shares during the period. Evergreen Capital Management LLC’s holdings in Stryker were worth $1,453,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Burkett Financial Services LLC purchased a new position in Stryker during the 4th quarter valued at about $25,000. Central Pacific Bank Trust Division bought a new position in shares of Stryker in the first quarter valued at approximately $39,000. Accent Capital Management LLC purchased a new position in Stryker during the fourth quarter valued at approximately $60,000. Sachetta LLC increased its holdings in Stryker by 16.3% during the 2nd quarter. Sachetta LLC now owns 242 shares of the medical technology company’s stock worth $80,000 after acquiring an additional 34 shares during the period. Finally, Hazlett Burt & Watson Inc. lifted its stake in Stryker by 17.9% in the 1st quarter. Hazlett Burt & Watson Inc. now owns 264 shares of the medical technology company’s stock worth $94,000 after purchasing an additional 40 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In related news, VP M Kathryn Fink sold 7,347 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total value of $2,696,202.06. Following the sale, the vice president now directly owns 10,042 shares of the company’s stock, valued at $3,685,213.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Viju Menon sold 600 shares of the firm’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the sale, the insider now owns 9,069 shares of the company’s stock, valued at $3,219,495. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP M Kathryn Fink sold 7,347 shares of the business’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the transaction, the vice president now directly owns 10,042 shares in the company, valued at $3,685,213.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 220,068 shares of company stock worth $71,811,372. 5.90% of the stock is currently owned by company insiders.

Stryker Trading Down 1.5 %

NYSE SYK opened at $361.00 on Wednesday. The firm has a market cap of $137.57 billion, a PE ratio of 41.21, a price-to-earnings-growth ratio of 2.83 and a beta of 0.91. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $374.63. The stock has a 50-day moving average of $346.43 and a 200-day moving average of $342.89. The company has a current ratio of 1.68, a quick ratio of 0.95 and a debt-to-equity ratio of 0.51.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.79 by $0.02. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The firm had revenue of $5.42 billion during the quarter, compared to the consensus estimate of $5.40 billion. During the same quarter in the previous year, the company posted $2.54 earnings per share. The business’s revenue was up 8.5% on a year-over-year basis. As a group, sell-side analysts forecast that Stryker Co. will post 12 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be issued a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date is Monday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 36.53%.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of recent analyst reports. Stifel Nicolaus reduced their price target on shares of Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Royal Bank of Canada restated an “outperform” rating and issued a $386.00 target price on shares of Stryker in a research note on Wednesday, July 31st. Truist Financial dropped their price target on Stryker from $364.00 to $345.00 and set a “hold” rating for the company in a research report on Thursday, August 1st. Piper Sandler restated an “overweight” rating and issued a $380.00 price objective on shares of Stryker in a research report on Tuesday, September 10th. Finally, The Goldman Sachs Group assumed coverage on shares of Stryker in a research note on Thursday, May 30th. They issued a “neutral” rating and a $372.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $378.58.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.